Easing Manufacturing Bottlenecks to Meet the Potential of mRNA
The use of mRNA technologies gained widespread recognition with its successful implementation in COVID-19 vaccines. However, manufacturing mRNA faces multiple challenges because of the novelty of its production and scaling processes and the lack of regulatory guidance, production capacity, and wide-spread manufacturing know-how.
Access insights from a panel of experts who convened to discuss strategies for overcoming these issues and creating a landscape where production of more potent mRNA vaccines is both more scalable and more accessible.
Don’t miss your free report from Scrip, presented in partnership with TriLink BioTechnologies.